SCHEMBL3398239

SCHEMBL3398239

O=CC(Br)c1ccc(Br)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 4/20 0.42
DGAT1 O75907 1/20 0.39
KDM1A O60341 2/20 0.33
KDM1B Q8NB78 1/20 0.33
ERN1 O75460 1/20 0.33
ALDH1A1 P00352 5/20 0.32
NPC1 O15118 3/20 0.32
LMNA P02545 3/20 0.32
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MAPT P10636 1/20 0.32
OPRM1 P35372 1/20 0.32
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PDPK1 O15530 1/20 0.31
CNR1 P21554 1/20 0.30
CNR2 P34972 1/20 0.30
AKR1B1 P15121 1/20 0.30
MMP1 P03956 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17604466 0.85 DGAT1 (0.35) APLNRDGAT1KDM1AKDM1BERN1
SCHEMBL1128052 0.82 CES2 (0.43) ALDH1A1
SCHEMBL1554814 0.79 MIF (0.39) ALDH1A1MAPTGAAL3MBTL1
SCHEMBL20551400 0.79 MDM2 (0.38) ERN1NPC1LMNARAB9ASMN1; SMN2
SCHEMBL12615183 0.79 APLNR (0.41) APLNRDGAT1KDM1AKDM1BERN1
SCHEMBL27747529 0.79 APLNR (0.48) APLNRDGAT1KDM1AKDM1BERN1
SCHEMBL3872105 0.77 APLNR (0.44) APLNRDGAT1KDM1AKDM1BALDH1A1
SCHEMBL15111101 0.77 CA1 (0.33) ERN1ALDH1A1LMNAMAPTKMT2A
SCHEMBL20551557 0.77 PDE2A (0.51) GAA
SCHEMBL27754728 0.77 APLNR (0.39) APLNRDGAT1KDM1AKDM1BERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023009785-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
EP-3829559-A1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION Merck Sharp & Dohme Corp. (US) 2021-06-09 EP disclosed
WO-2020028150-A1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME CORP. (US) 2020-02-06 WO disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
EP-2250163-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2010-11-17 EP disclosed
WO-2009102318-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 WO disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
EP-2049114-A2 HEPATITIS C VIRUS INHIBITORS Brystol-Myers Squibb Company (US) 2009-04-22 EP disclosed
EP-2049116-A2 HEPATITIS C VIRUS INHIBITORS Brystol-Myers Squibb Company (US) 2009-04-22 EP disclosed
EP-2049522-A2 HEPATITIS C VIRUS INHIBITORS Brystol-Myers Squibb Company (US) 2009-04-22 EP disclosed
WO-2008021936-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO disclosed
WO-2008021928-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO disclosed